Multiplex PCR Panel Testing Market (2026 - 2033)

Multiplex PCR Panel Testing Market Summary

The global multiplex PCR panel testing market size was valued at USD 2.6 billion in 2025 and is projected to grow from USD 2.8 billion in 2026 to USD 4.9 billion by 2033, at a CAGR of 8.4% from 2026 to 2033. The market in North America dominated with a revenue share of 41.1% in 2025. The market growth is driven by the growing prevalence of respiratory and gastrointestinal infections and strong demand for rapid syndromic testing in infectious disease diagnostics.

Moreover, advancements in multiplexing technologies, laboratory automation, and high-throughput molecular workflows are supporting broader adoption of multiplex PCR panels across healthcare settings. Expanding utilization of decentralized and point-of-care molecular diagnostic platforms is further contributing to market growth.

The rising prevalence of respiratory and gastrointestinal infections is driving market growth due to growing demand for rapid and accurate pathogen identification. Multiplex PCR panel enables simultaneous detection of multiple viral, bacterial, and parasitic pathogens from a single sample, making them well-suited for managing infections associated with overlapping clinical symptoms. The growing incidence of respiratory infections, including influenza, RSV, pneumonia, and other lower respiratory tract infections, along with outbreaks of gastrointestinal infections such as norovirus and Shigella, is accelerating the adoption of syndromic molecular diagnostics across hospitals and clinical laboratories. According to a study published in The Lancet in September 2024, Global Burden of Disease analyses estimated that lower respiratory infections accounted for approximately 344 million cases globally and continued to rank among the leading infectious causes of mortality worldwide. Moreover, the Centers for Disease Control and Prevention reported in April 2026 that nearly 2,500 norovirus outbreaks occur annually in the U.S., while norovirus continues to cause approximately 685 million cases of acute gastroenteritis globally each year.

The growing demand for rapid syndromic testing in infectious disease diagnostics is supporting market growth due to the need for faster and more comprehensive pathogen detection. Syndromic multiplex PCR panel enables simultaneous identification of multiple pathogens associated with similar clinical symptoms from a single patient sample, reducing diagnostic turnaround time compared with conventional culture-based and single-target testing methods. Healthcare providers are adopting rapid syndromic testing to improve early diagnosis, patient triage, infection control, and treatment selection, particularly in respiratory, gastrointestinal, bloodstream, and central nervous system infections. The growing clinical emphasis on antimicrobial stewardship and reduction of unnecessary antibiotic use is further supporting the adoption of multiplex syndromic molecular diagnostics across hospitals, emergency departments, and clinical laboratories.

Continuous advancements in multiplexing and laboratory automation technologies are driving market growth by improving testing efficiency, workflow automation, and diagnostic accuracy. Innovations in high-plex assay development, automated sample preparation, integrated molecular systems, and real-time data analysis are enabling simultaneous detection of multiple pathogens with faster turnaround times and minimal hands-on time. These technologies also support higher laboratory throughput and improved operational efficiency in clinical settings. For instance, in January 2026, Cepheid received U.S. FDA clearance for the Xpert GI Panel, a multiplex PCR assay designed for simultaneous detection of 11 gastrointestinal bacterial, viral, and parasitic pathogens from a single stool sample. The panel utilizes Cepheid’s 10-color multiplexing technology on GeneXpert systems, supporting rapid syndromic testing and automated molecular diagnostic workflows.

Market Concentration & Characteristics

The multiplex PCR panel testing industry demonstrates a high degree of innovation, driven by continuous advancements in multiplexing capabilities, assay sensitivity, laboratory automation, and syndromic molecular diagnostics. Companies are increasingly developing high-plex PCR panels capable of simultaneously detecting multiple bacterial, viral, and parasitic pathogens from a single sample with faster turnaround times and minimal hands-on intervention. Integration of automated sample preparation, real-time data analysis, and advanced molecular workflows is improving diagnostic efficiency across clinical laboratories and decentralized healthcare settings. According to the article published by Cepheid in January 2026, the company highlighted advancements in its multiplex molecular diagnostics portfolio through syndromic testing assays capable of simultaneously detecting multiple respiratory, gastrointestinal, and women’s health pathogens on GeneXpert systems, supporting rapid and decentralized infectious disease diagnostics.

The multiplex PCR panel testing industry is witnessing a moderate to high level of strategic expansion activity, driven by increasing demand for advanced molecular diagnostics, syndromic testing capabilities, and expanded infectious disease testing portfolios. Companies are actively pursuing partnerships, portfolio expansion initiatives, and strategic collaborations to strengthen multiplex molecular diagnostic technologies, enhance automation capabilities, and expand their geographic presence. In June 2024, QIAGEN expanded its syndromic testing and multiplex PCR capabilities through portfolio expansion initiatives focused on respiratory and gastrointestinal molecular diagnostic panels, reflecting increasing industry investment in rapid multiplex infectious disease testing technologies

The multiplex PCR panel testing industry is significantly influenced by regulatory frameworks governing molecular diagnostics and infectious disease testing. Regulatory agencies such as the U.S. Food and Drug Administration play an important role in ensuring the safety, accuracy, and clinical performance of multiplex PCR assays before commercialization. Growing regulatory clearances for syndromic molecular panels are supporting market growth by accelerating the adoption of rapid infectious disease diagnostics across hospitals and clinical laboratories. However, stringent regulatory requirements related to clinical validation, quality compliance, and post-market surveillance may increase product development timelines and commercialization costs for manufacturers operating in the multiplex molecular diagnostics market.

The multiplex PCR panel testing industry is witnessing strong regional expansion, driven by increasing adoption of molecular diagnostics, growing investments in infectious disease testing infrastructure, and strong demand for rapid syndromic testing across healthcare systems. Market participants are expanding their commercial presence through distribution partnerships, laboratory collaborations, and deployment of automated multiplex PCR platforms across hospitals and diagnostic laboratories. Moreover, growing regulatory approvals, expansion of decentralized molecular testing capabilities, and improving accessibility to advanced diagnostic technologies in emerging healthcare markets are supporting broader regional penetration of multiplex PCR panel testing solutions.

Disease Application Insights

Respiratory panel dominated the market with the largest revenue share of 30.51% in 2025, driven by the rising prevalence of respiratory infections and increasing adoption of rapid syndromic molecular diagnostics across hospitals and clinical laboratories. Respiratory multiplex PCR panels enable simultaneous detection of multiple viral and bacterial pathogens, including influenza, RSV, and SARS-CoV-2, supporting faster diagnosis and treatment decisions. Growing utilization of multiplex respiratory panels for infection control and antimicrobial stewardship is further supporting segment growth. For instance, in September 2025, Roche Diagnostics highlighted advancements in its multiplex molecular diagnostics portfolio through the cobas Respiratory flex solution, which enables simultaneous detection and differentiation of up to 12 respiratory viral targets from a single test, supporting flexible and automated syndromic PCR testing workflows.

The gastrointestinal panel segment is projected to grow at a CAGR of 10.89% over the forecast period, fueled by the rising prevalence of gastrointestinal infections, increasing adoption of syndromic molecular diagnostics, and growing demand for rapid detection of bacterial, viral, and parasitic pathogens from a single sample. Gastrointestinal multiplex PCR panels are increasingly utilized across hospitals and clinical laboratories due to their ability to improve diagnostic accuracy, reduce turnaround time, and support timely treatment decisions. In February 2025, bioMérieux received U.S. FDA clearance for the BIOFIRE FILMARRAY Gastrointestinal Panel Mid, a midplex PCR panel capable of simultaneously detecting 11 gastrointestinal pathogens from a single stool sample in approximately one hour, supporting rapid syndromic infectious disease diagnostics and streamlined laboratory workflows.

End Use Insights

Hospitals & clinics dominated the market with the largest revenue share of 34.39% in 2025 due to increasing adoption of rapid syndromic molecular diagnostics for infectious disease management, rising patient volumes requiring timely pathogen detection, and growing utilization of multiplex PCR panel across emergency departments, intensive care units, and hospital laboratories. Hospitals and clinics increasingly rely on multiplex PCR testing for simultaneous detection of multiple respiratory, gastrointestinal, and bloodstream pathogens to support faster clinical decision-making, infection control, and antimicrobial stewardship initiatives. For instance, in April 2026, Seegene showcased enhanced automated PCR workflow solutions and syndromic multiplex PCR testing capabilities at ESCMID Global 2026, supporting simultaneous multi-pathogen detection and improved laboratory workflow efficiency across hospital and clinical laboratory settings.

The physician office labs segment is projected to grow at a CAGR of 9.01% over the forecast period, owing to increasing preference for decentralized and near-patient molecular diagnostics, rising demand for rapid infectious disease testing in outpatient settings, and growing adoption of compact multiplex PCR platforms with simplified workflows. Physician office laboratories are increasingly utilizing multiplex PCR panels for rapid detection of respiratory, gastrointestinal, and sexually transmitted infections to support same-visit clinical decision-making and timely treatment initiation. Growing availability of automated sample-to-answer multiplex molecular systems with minimal hands-on requirements is further supporting the adoption of syndromic PCR testing across physician office laboratory settings.

Testing Setting Insights

Centralized laboratory testing dominated the market with the largest revenue share of 50.52% in 2025, due to high testing volumes, increasing adoption of high-throughput molecular diagnostic systems, and growing demand for comprehensive syndromic infectious disease testing across hospital and reference laboratories. Centralized laboratories extensively utilize a multiplex PCR panel for simultaneous detection of multiple respiratory, gastrointestinal, bloodstream, and central nervous system pathogens, supporting improved diagnostic efficiency and faster clinical decision-making. These laboratories are increasingly integrating automated sample preparation, high-capacity molecular analyzers, and advanced multiplexing technologies to improve workflow efficiency and reduce turnaround times. In addition, growing emphasis on antimicrobial stewardship, outbreak surveillance, and rapid multi-pathogen detection is further accelerating the adoption of multiplex PCR panels in centralized laboratory settings.

Near-patient testing is projected to grow at a CAGR of 9.96% over the forecast period, driven by increasing demand for rapid decentralized infectious disease diagnostics, growing adoption of point-of-care molecular testing, and rising need for faster clinical decision-making in emergency departments, outpatient clinics, and urgent care settings. Near-patient multiplex PCR platforms enable simultaneous detection of multiple respiratory, gastrointestinal, and sexually transmitted pathogens with minimal hands-on time and faster turnaround compared with conventional laboratory testing. Increasing availability of compact sample-to-answer molecular systems and automated syndromic testing workflows is further supporting the adoption of multiplex PCR panels across decentralized healthcare environments, thereby contributing to overall market growth.

Throughput Insights

The high-throughput lab systems segment dominated the market with the largest revenue share of 42.77% in 2025, driven by growing demand for large-scale infectious disease testing, adoption of automated molecular diagnostic platforms, and utilization of multiplex PCR panels across centralized laboratories and hospital networks. High-throughput multiplex PCR systems enable simultaneous processing of large sample volumes with rapid turnaround times, supporting efficient detection of multiple respiratory, gastrointestinal, bloodstream, and central nervous system pathogens from a single workflow. These systems also improve laboratory productivity through automation, reduced manual intervention, and streamlined sample processing. For instance, in April 2026, Seegene showcased its enhanced CURECA automated PCR workflow platform designed to integrate preprocessing, nucleic acid extraction, amplification, and result analysis, supporting high-throughput syndromic multiplex PCR testing across centralized laboratory environments.

The Low-throughput Systems (POC) segment is projected to grow at a CAGR of 11.34% over the forecast period due to increasing demand for rapid point-of-care infectious disease diagnostics, growing adoption of decentralized molecular testing, and rising preference for compact sample-to-answer multiplex PCR platforms in outpatient and emergency care settings. Low-throughput multiplex PCR systems enable rapid simultaneous detection of multiple pathogens with minimal hands-on time, supporting faster clinical decision-making and timely treatment initiation. These systems are increasingly utilized across physician office laboratories, urgent care centers, pharmacies, and community healthcare settings due to their operational simplicity, portability, and ability to deliver rapid syndromic testing results outside traditional centralized laboratory environments.

Regional Insights

North America dominated the global multiplex PCR panel testing market and accounted for the largest revenue share in 2025, driven by strong adoption of advanced molecular diagnostics, high prevalence of infectious diseases, and widespread utilization of syndromic testing across hospitals and reference laboratories. The region benefits from well-established healthcare infrastructure, favorable reimbursement frameworks, and a strong presence of major molecular diagnostics companies. Growing implementation of rapid multiplex PCR panels for respiratory, gastrointestinal, bloodstream, and sexually transmitted infection testing is supporting market growth across centralized and decentralized healthcare settings. QIAGEN’s launch of multiple QIAcuity digital PCR assays in September 2024, targeting infectious diseases including STIs and respiratory pathogens, reflects this shift toward precision diagnostics. At the same time, companies continue to balance centralized high-throughput systems with decentralized platforms to address diverse laboratory needs across the region. Moreover, growing emphasis on antimicrobial stewardship, infection surveillance, and rapid outbreak response is accelerating the adoption of automated syndromic molecular diagnostics throughout the region.

U.S. Multiplex PCR Panel Testing Market Trends

The multiplex PCR panel testing market in the U.S. dominates North America due to growing demand for rapid infectious disease diagnostics, high adoption of syndromic molecular testing, and strong integration of automated PCR platforms across hospitals and clinical laboratories. The growing prevalence of respiratory and gastrointestinal infections, along with a strong focus on antimicrobial stewardship and timely clinical decision-making, is supporting broader utilization of multiplex PCR panels. The country also benefits from advanced laboratory infrastructure, strong regulatory support for molecular diagnostics, and expanding deployment of decentralized molecular testing systems across emergency departments, physician office laboratories, and urgent care centers. Moreover, continuous technological advancements in multiplexing, workflow automation, and sample-to-answer molecular systems are further contributing to market expansion.

Europe Multiplex PCR Panel Testing Market Trends

The multiplex PCR panel testing market in Europe represents a significant share, supported by growing adoption of molecular diagnostics, expanding investment in infectious disease surveillance, and strong demand for rapid syndromic testing across healthcare systems. A notable regulatory-driven milestone includes Eurobio Scientific receiving IVDR CE marking in April 2023 for its EurobioPlex multiplex PCR assays (Class C), enabling continued commercialization of infectious disease panels under the new framework. These developments reflect how compliance is not only a barrier but also a competitive differentiator in Europe. Expansion of hospital laboratory automation, growing awareness regarding antimicrobial resistance, and a strong focus on infection prevention are contributing to broader adoption of multiplex PCR panels across the region. Moreover, supportive regulatory frameworks for in vitro diagnostics and expanding utilization of multiplex molecular testing for respiratory, gastrointestinal, and bloodstream infections are supporting market growth. The growing implementation of decentralized molecular diagnostic workflows and public health initiatives for infectious disease monitoring is further strengthening demand for multiplex PCR testing solutions in Europe.

The UK multiplex PCR panel testing market is driven by growing demand for rapid molecular diagnostics, rising burden of respiratory infections, and expanding adoption of syndromic PCR testing across National Health Service laboratories and hospitals. Strong focus on infection control, antimicrobial stewardship, and timely pathogen detection is supporting broader integration of multiplex molecular diagnostics in clinical workflows. The country is also witnessing growing utilization of automated and decentralized PCR testing platforms to improve diagnostic turnaround times and laboratory efficiency. Moreover, the ongoing modernization of diagnostic infrastructure and a stronger emphasis on early infectious disease detection across emergency and outpatient care settings are contributing to market growth.

The multiplex PCR panel testing market in Germany is supported by advanced clinical laboratory infrastructure, strong adoption of molecular diagnostic technologies, and growing demand for high-throughput infectious disease testing. Hospitals and diagnostic laboratories across the country are utilizing multiplex PCR panels for simultaneous detection of respiratory, gastrointestinal, and bloodstream pathogens to improve diagnostic accuracy and clinical efficiency. Strong focus on laboratory automation, infection surveillance, and antimicrobial resistance monitoring is further supporting market expansion. Moreover, expanding integration of syndromic molecular diagnostics into routine clinical testing workflows and growing demand for rapid decentralized molecular testing are contributing to broader adoption of multiplex PCR technologies across the German healthcare system.

Asia Pacific Multiplex PCR Panel Testing Market Trends

The multiplex PCR panel testing market in the Asia Pacific is witnessing substantial growth due to the growing prevalence of infectious diseases, expanding healthcare infrastructure, and adoption of molecular diagnostics across emerging economies. Expanding investments in hospital laboratory modernization, growing awareness regarding rapid infectious disease detection, and improving accessibility to molecular testing technologies are supporting market expansion across the region. Countries throughout the Asia Pacific are adopting multiplex PCR panels for respiratory, gastrointestinal, and sexually transmitted infection testing to improve clinical efficiency and outbreak management. Moreover, strong demand for decentralized diagnostic solutions, expanding healthcare expenditure, and growth of local molecular diagnostics manufacturing capabilities are accelerating the adoption of multiplex PCR technologies across regional healthcare systems.

Japan multiplex PCR panel testing market is driven by advanced healthcare infrastructure, growing adoption of automated molecular diagnostics, and strong demand for rapid infectious disease testing in hospitals and clinical laboratories. The country’s aging population and growing focus on early disease detection are supporting broader utilization of syndromic multiplex PCR testing for respiratory and gastrointestinal infections. Moreover, strong emphasis on laboratory efficiency, infection prevention, and high diagnostic accuracy is encouraging the adoption of automated multiplex molecular platforms across healthcare settings. Expanding investment in advanced diagnostic technologies and growing integration of decentralized molecular testing solutions are further contributing to market growth in Japan.

The multiplex PCR panel testing market in China is experiencing strong growth due to expanding molecular diagnostics capabilities, growing infectious disease surveillance initiatives, and expanding healthcare investments across hospital and laboratory infrastructure. Strong demand for rapid pathogen detection, growing utilization of syndromic molecular diagnostics, and expansion of domestic molecular diagnostics manufacturing are supporting broader adoption of multiplex PCR panels across the country. Moreover, growing focus on public health preparedness, outbreak monitoring, and laboratory automation is accelerating implementation of high-throughput multiplex PCR systems in centralized laboratories. Expanding deployment of decentralized molecular testing solutions across community healthcare settings is also contributing to market expansion in China.

Latin America Multiplex PCR Panel Testing Market Trends

The multiplex PCR panel testing market in Latin America is growing due to the rising burden of infectious diseases, improving access to molecular diagnostics, and expanding investment in healthcare infrastructure across the region. Hospitals and diagnostic laboratories are adopting multiplex PCR panels to improve the rapid detection of respiratory, gastrointestinal, and vector-borne infections. Growing awareness regarding syndromic molecular testing, stronger focus on outbreak surveillance, and expansion of public healthcare diagnostic programs are supporting market growth. Moreover, improving the availability of automated molecular diagnostic platforms and the growing demand for decentralized infectious disease testing solutions are contributing to the broader adoption of multiplex PCR technologies across Latin American healthcare systems.

Middle East & Africa Multiplex PCR Panel Testing Market Trends

The multiplex PCR panel testing market in MEA is witnessing gradual growth due to expanding investment in healthcare infrastructure, growing awareness regarding molecular diagnostics, and strong demand for rapid infectious disease testing. Expansion of hospital laboratory capabilities and a stronger focus on improving diagnostic efficiency are supporting the adoption of multiplex PCR panels across the region. Governments and healthcare organizations are emphasizing infectious disease surveillance, outbreak preparedness, and modernization of laboratory systems to strengthen healthcare delivery. Moreover, growing implementation of automated molecular testing platforms and improving access to decentralized diagnostic technologies are contributing to broader utilization of multiplex PCR testing solutions across the Middle East & African healthcare settings.

Key Multiplex PCR Panel Testing Company Insights

The market is moderately consolidated, with competition driven by technological advancements in syndromic molecular diagnostics, expansion of infectious disease testing portfolios, and adoption of automated multiplex PCR platforms across centralized and decentralized healthcare settings. Key market participants are focusing on the development of high-plex molecular assays, workflow automation, rapid turnaround capabilities, and the expansion of respiratory, gastrointestinal, bloodstream, and sexually transmitted infection testing portfolios to strengthen their competitive positioning. Companies are also investing in regulatory approvals, strategic collaborations, and the commercialization of decentralized molecular testing platforms to expand market reach.

Recent Developments

• In March 2026, QIAGEN received U.S. FDA clearance for its QIAstat-Dx Gastrointestinal Panel on the fully automated QIAstat-Dx Rise syndromic testing platform. The clearance enables laboratories to perform both respiratory and gastrointestinal multiplex PCR testing on a single high-throughput automated system capable of processing up to 160 tests per day with minimal hands-on time, supporting expansion of rapid syndromic molecular diagnostics across clinical laboratory settings.

• In March 2026, bioMérieux announced that its BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini achieved U.S. FDA 510(k) clearance and a CLIA waiver for anterior nasal swab specimens, broadening rapid, point‑of‑care respiratory testing options and supporting expanded use in urgent care and clinic settings.

• In May 2025, DiaSorin received U.S. FDA 510(k) clearance for the updated NxTAG Respiratory Pathogen Panel v2, a high-throughput syndromic multiplex molecular assay capable of simultaneously detecting SARS-CoV-2, 19 viral, and two bacterial respiratory pathogens from a single sample. The panel was designed to support high-volume respiratory testing workflows and strengthen multiplex respiratory diagnostics across centralized laboratory settings.

Multiplex PCR Panel Testing Market Report Scope

Global Multiplex PCR Panel Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global multiplex PCR panel testing market report based on disease application, end use, throughput, testing setting, and region:

• Disease Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Respiratory Panel

  • Gastrointestinal Panel

  • Sexually Transmitted Infection (STI) Panel

  • Bloodstream / Sepsis Panel

  • Central Nervous System (CNS) Panel

  • Tropical Disease Panel

  • Other Panel

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals & Clinics (dominant)

  • Diagnostic Laboratories (central labs)

  • Ambulatory Care Centers

  • Academic & Research Institutes

  • Public Health Laboratories

  • Physician Office Labs (POLs)

  • Point-of-Care Settings

• Testing Setting Outlook (Revenue, USD Million, 2021 - 2033)

  • Centralized Laboratory Testing

  • Near-Patient Testing

  • Others

• Throughput Outlook (Revenue, USD Million, 2021 - 2033)

  • Low-throughput systems (POC)

  • Medium-throughput systems

  • High-throughput lab systems

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait